Esperion Therapeutics (ESPR) Competitors

Esperion Therapeutics logo
$1.86 -0.01 (-0.53%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$1.87 +0.01 (+0.54%)
As of 02/14/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESPR vs. KNSA, GPCR, ARQT, NRIX, INDV, ARDX, ARVN, SNDX, VIR, and ANIP

Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX), Indivior (INDV), Ardelyx (ARDX), Arvinas (ARVN), Syndax Pharmaceuticals (SNDX), Vir Biotechnology (VIR), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.

Esperion Therapeutics vs.

Esperion Therapeutics (NASDAQ:ESPR) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Esperion Therapeutics received 454 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 70.15% of users gave Esperion Therapeutics an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Esperion TherapeuticsOutperform Votes
625
70.15%
Underperform Votes
266
29.85%
Kiniksa PharmaceuticalsOutperform Votes
171
65.02%
Underperform Votes
92
34.98%

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Esperion Therapeutics presently has a consensus target price of $6.75, suggesting a potential upside of 262.90%. Kiniksa Pharmaceuticals has a consensus target price of $36.60, suggesting a potential upside of 85.41%. Given Esperion Therapeutics' higher probable upside, equities research analysts plainly believe Esperion Therapeutics is more favorable than Kiniksa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Esperion Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kiniksa Pharmaceuticals has higher revenue and earnings than Esperion Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$116.33M3.15-$209.25M-$0.64-2.91
Kiniksa Pharmaceuticals$384.10M3.71$14.08M-$0.14-141.00

Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat Kiniksa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Esperion Therapeutics-29.37% N/A -10.77%
Kiniksa Pharmaceuticals -2.36%-7.31%-5.95%

Esperion Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

In the previous week, Esperion Therapeutics had 4 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 13 mentions for Esperion Therapeutics and 9 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.75 beat Esperion Therapeutics' score of 0.22 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Esperion Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Kiniksa Pharmaceuticals beats Esperion Therapeutics on 11 of the 18 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESPR vs. The Competition

MetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$366.49M$6.85B$5.77B$9.21B
Dividend YieldN/A2.88%5.27%3.99%
P/E Ratio-2.919.0525.6519.13
Price / Sales3.15318.75475.1180.74
Price / CashN/A75.4646.0638.90
Price / Book-0.485.537.275.05
Net Income-$209.25M$123.46M$3.19B$222.81M
7 Day PerformanceN/A1.37%1.67%1.29%
1 Month Performance-15.84%2.09%4.11%1.52%
1 Year Performance-30.86%1.28%22.10%16.53%

Esperion Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESPR
Esperion Therapeutics
4.5871 of 5 stars
$1.86
-0.5%
$6.75
+262.9%
-30.9%$366.49M$116.33M-2.91200Short Interest ↓
Analyst Revision
KNSA
Kiniksa Pharmaceuticals
3.6058 of 5 stars
$19.49
flat
$36.60
+87.8%
-1.0%$1.41B$270.26M-139.35220
GPCR
Structure Therapeutics
2.7653 of 5 stars
$24.02
-12.3%
$81.29
+238.4%
-46.7%$1.38BN/A-32.54136Short Interest ↓
ARQT
Arcutis Biotherapeutics
2.786 of 5 stars
$11.64
+0.3%
$16.60
+42.6%
+37.4%$1.37B$59.61M-6.53150
NRIX
Nurix Therapeutics
2.2429 of 5 stars
$18.01
-4.6%
$31.12
+72.8%
+78.2%$1.37B$54.55M-6.23300
INDV
Indivior
2.5632 of 5 stars
$9.57
-0.2%
$16.00
+67.3%
-44.0%$1.32B$1.09B-239.071,164Short Interest ↑
Positive News
ARDX
Ardelyx
3.7479 of 5 stars
$5.58
-0.1%
$9.42
+68.9%
-36.0%$1.32B$124.46M-18.5590Short Interest ↑
ARVN
Arvinas
2.8622 of 5 stars
$18.95
+1.3%
$61.45
+224.4%
-65.0%$1.30B$78.50M-4.05420Earnings Report
Short Interest ↑
Analyst Revision
SNDX
Syndax Pharmaceuticals
3.8204 of 5 stars
$15.12
-2.6%
$36.20
+139.4%
-33.6%$1.29B$16M-4.16110
VIR
Vir Biotechnology
4.1805 of 5 stars
$9.33
-5.2%
$34.83
+273.5%
-5.9%$1.28B$86.18M-2.37580
ANIP
ANI Pharmaceuticals
4.4486 of 5 stars
$60.33
-0.4%
$77.71
+28.8%
-1.3%$1.27B$486.82M-109.72600

Related Companies and Tools


This page (NASDAQ:ESPR) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners